TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-02	US$1.570	+1.62%	15,501
26-10-01	US$1.545	-8.04%	16,712
26-09-30	US$1.680	+3.07%	6,733
26-09-29	US$1.630	-4.68%	11,006
26-09-28	US$1.710	+1.18%	40,680

Delayed Quote Nasdaq

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq 16:00:00 2026-10-02 EDT			5-day change	1st Jan Change
1.570 ^USD	+1.62%		-7.10%	-77.01%

09-28	TransCode Therapeutics, Inc. Reports Updated Clinical Data from Its Phase 1A Clinical Trial of TTX-MC138	CI
09-22	TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology	CI

Market Cap	26.58M 23.62M 22.04M 20.09M 37.89M 2.56B 38.25M 267M 103M 1.31B 99.8M 97.63M 4.19B	P/E 2024	-0.07x	P/E 2025	-0.13x
Enterprise Value	8.77M 7.79M 7.27M 6.63M 12.5M 843M 12.62M 87.99M 34.1M 431M 32.92M 32.2M 1.38B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	98.22%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	RNAZ	Delayed
CBOE	RNAZ	Real-time

09-28	TransCode Therapeutics, Inc. Reports Updated Clinical Data from Its Phase 1A Clinical Trial of TTX-MC138	CI
09-22	TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology	CI
09-16	TransCode Therapeutics, Inc. - Special Call
09-10	Transcode Therapeutics, Inc. Announces CFO Changes, Effective September 9, 2026	CI
09-10	Transcode Therapeutics, Inc. Announces Management Changes, Effective from September 9, 2026	CI
08-31	TransCode Therapeutics, Inc Announces Publication Demonstrating Survival Benefit Of TTX-MC138 In Preclinical Model Of Breast Cancer Bone Metastasis	CI
08-14	TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-18	TransCode Therapeutics, Inc. - Special Call
06-03	TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a	MT
06-03	Transcode Therapeutics Completes Phase 1A Clinical Trial and Advances Ttx-Mc138 to Phase 2A Development	CI
05-27	TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 In Patients With ctDNA Positive Colorectal Cancer	CI
05-15	TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-01	TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal	MT

TransCode Therapeutics, Inc. Stock

Stocks

RNAZ

US89357L5012

Biotechnology & Medical Research

Valuation: TransCode Therapeutics, Inc.

Chart: TransCode Therapeutics, Inc.

Latest news: TransCode Therapeutics, Inc.

Last Transcript: TransCode Therapeutics, Inc.

Analysts' recommendations: TransCode Therapeutics, Inc.

Press Releases: TransCode Therapeutics, Inc.

News in other languages: TransCode Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: TransCode Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

25-10-14	Transcode Therapeutics completes phase 1a trial with TTX-MC138 in metastatic disease at ESMO - SEC filing	RE
22-11-15	HC Wainwright Adjusts Price Target on TransCode Therapeutics to $6 From $10, Maintains Buy Rating	MT
22-06-07	HC Wainwright Starts TransCode Therapeutics at Buy With $10 Price Target	MT

09-16	Join Today's Live Investor Webinar with TransCode Therapeutics	AQ
09-03	Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer	AQ
08-07	Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV	AQ
03-03	TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients	PR
02-23	TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development	PR

1 day	+1.62%
1 week	-7.10%
Current month	-6.55%
1 month	-21.89%
3 months	-81.77%
6 months	-81.74%
Current year	-77.01%

1 week	1.52	1.81
1 month	1.52	2.39
Current year	1.52	12.6
1 year	1.52	20.99
3 years	1.52	19,588.78
5 years	1.52	2,557,658.19
10 years	1.52	5,174,452.99

Manager	Title	Age	Since
Philippe Calais CEO	Chief Executive Officer	67	2025-10-05
Zdravka Medarova CTO	Chief Tech/Sci/R&D Officer	52	2021-09-30
John Tattory DFI	Director of Finance/CFO	61	2026-09-09

Director	Title	Age	Since
Philippe Calais CHM	Chairman	67	2021-02-17
Erik Manting BRD	Director/Board Member	54	2020-12-19
Magda Marquet BRD	Director/Board Member	67	2020-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/9/26	Thomas Fitzgerald	Free	Chief Executive Officer	185,000	1.0927%
8/3/26	CK LIFE SCIENCES INTERNATIONAL (HOLDINGS), INC.	Conversion	Company	13,834,441	81.7120%
7/27/26	CK LIFE SCIENCES INTERNATIONAL (HOLDINGS), INC.	Other	Company	300,040	1.7722%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSCODE THERAPEUTICS, INC.	+1.62%	-7.10%	-85.16%	-99.99%	26.16M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.41B
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	59.26B
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	47.14B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+26.36%	+33.18%	42.91B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+352.17%	+689.61%	44.13B
BEONE MEDICINES AG	-0.20%	-0.77%	+3.74%	+100.60%	40.79B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.77B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+19.50%	29.31B
INSMED INCORPORATED	+2.33%	-5.69%	-27.28%	+338.00%	23.71B
Average	+0.19%	-1.42%	+38.43%	+133.46%	39.25B
Weighted average by Cap.	+0.24%	-0.98%	+57.34%	+150.71%

	2024	2025
Net sales	-	-
Net income	-16.75M -14.89M -13.89M -12.66M -23.88M -1.61B -24.11M -168M -65.16M -823M -62.91M -61.54M -2.64B	-34.66M -30.8M -28.74M -26.2M -49.41M -3.33B -49.87M -348M -135M -1.7B -130M -127M -5.47B
Net Debt	-5.77M -5.13M -4.79M -4.36M -8.23M -555M -8.31M -57.93M -22.45M -284M -21.67M -21.2M -910M	-17.81M -15.83M -14.77M -13.46M -25.39M -1.71B -25.63M -179M -69.27M -875M -66.88M -65.43M -2.81B